Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG.
OBJECTIVE
A new chromatographic step for the selective binding of abnormal prion protein (PrP(Sc)) was developed, and optimization for PrP(Sc) capture was achieved by binding to an affinity ligand attached to synthetic resin particles. This step was implemented into the manufacturing process of the solvent/detergent (S/D)-treated biopharmaceutical quality plasma Octaplas to further improve the safety margin in terms of risk for variant Creutzfeldt-Jakob disease (vCJD) transmission.


METHODS
Intermediates and Octaplas final container material, spiked with hamster brain-derived PrP(Sc)-containing fractions, were used for experiments to establish the feasibility of introducing this novel chromatography step. The binding capacity per millilitre of ligand gel was determined under the selected manufacturing conditions. In addition, the specificity of the ligand gel to bind PrP(Sc) from human sources was investigated. A validated Western blot test was used for the identification and quantification of PrP(Sc).


RESULTS
A reduction factor of > or = 3.0 log(10) could be demonstrated by Western blotting, utilizing the relevant Octaplas matrix from manufacturing. In this particular cell-free plasma solution, the PrP(Sc) binding capacity of the selected gel was very high (> or = 6 log(10) ID(50)/ml, equivalent to roughly 10 log(10) ID(50)/column at manufacturing scale). The gel binds specifically PrP(Sc) from both animal (hamster and mouse) and human (sporadic and variant CJD) sources.


CONCLUSIONS
This new single-use, disposable PrP(Sc)-harvesting gel ensures a very high capacity in terms of removing the pathogenic agent causing vCJD from the new generation OctaplasLG, in the event that prions can be found in plasma from donors incubating the disease and thereby contaminating the raw material plasma used for manufacturing.
Neisser-Svae
A
A
Research & Development, Octapharma Pharmazeutika Produktionsges.m.b.H, Vienna, Austria. andrea.neisser-svae@octapharma.com
Bailey
A
A
Gregori
L
L
Heger
A
A
Jordan
S
S
Behizad
M
M
Reichl
H
H
Römisch
J
J
Svae
T-E
TE
D000818:Animals; D017848:Blood-Borne Pathogens / Q000302:isolation & purification*; D015153:Blotting, Western; D002846:Chromatography, Affinity / Q000379:methods*; D007562:Creutzfeldt-Jakob Syndrome / Q000517:prevention & control; D006224:Cricetinae; D003902:Detergents / Q000494:pharmacology*; D005240:Feasibility Studies; D016098:Gerstmann-Straussler-Scheinker Disease; D006801:Humans; D008647:Mesocricetus; D051379:Mice; D010865:Pilot Projects; D010949:Plasma / Q000187:drug effects*; D018620:PrPSc Proteins / Q000032:analysis / Q000302:isolation & purification*; D011485:Protein Binding; D015203:Reproducibility of Results; D012117:Resins, Synthetic / Q000494:pharmacology*; D012608:Scrapie; D012997:Solvents / Q000494:pharmacology*; D016060:Sorption Detoxification / Q000379:methods*; D013997:Time Factors
D003902:Detergents; D018620:PrPSc Proteins; D012117:Resins, Synthetic; D012997:Solvents